Dimitrios Roukas1, Anastasios Kouzoupis2, Despoina Spyropoulou3, George Papanastasiou4, Evangelos Tsiambas5,6,7, George Tsouvelas8, Evangelos Falidas9, Vasileios Ragos4, Dimitrios Peschos10, Loukas Manaios11, Spyros Katsinis12, Arezina Manoli12, Sotirios Papouliakos12, Andreas C Lazaris7, Nikolaos Kavantzas7. 1. Department of Psychiatry, 417 VA (NIMTS) Hospital, Athens, Greece. 2. Department of Psychiatry, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 3. Department of Radiation Oncology, Medical School, University of Patras, Patras, Greece. 4. Department of Maxillofacial Surgery, School of Medicine, University of Ioannina, Ioannina, Greece. 5. Department of Maxillofacial Surgery, School of Medicine, University of Ioannina, Ioannina, Greece; tsiambasecyto@yahoo.gr. 6. Department of Cytology, 417 VA (NIMTS) Hospital, Athens, Greece. 7. Department of Pathology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 8. Department of Nursing, University of West Attica, Athens, Greece. 9. Department of Surgery, Halkida General Hospital, Halkida, Greece. 10. Department of Physiology, School of Medicine, University of Ioannina, Ioannina, Greece. 11. Department of Surgery, Bioclinic Medical Center, Athens, Greece. 12. Department of Otorhinolaryngology, Thoracic Diseases General Hospital "Sotiria", Athens, Greece.
Abstract
BACKGROUND/AIM: Meningiomas represent the main intracranial primary central nervous system (CNS) tumour in adults worldwide. Oncogenes' over-activation combined with suppressor genes' silencing affect negatively the biological behavior of these neoplasms. This study aimed to explore the impact of p53 suppressor gene expression in meningiomas' clinic-pathological features based on a combination of sophisticated techniques. MATERIALS AND METHODS: Fifty (n=50) meningiomas were included in the study, comprising a broad spectrum of histopathological subtypes. An immunohistochemistry assay was applied on tissue microarray cores followed by digital image analysis. RESULTS: p53 protein over-expression (high staining intensity levels) was observed in 27/50 (54%) cases, whereas the rest (23/50-/46%) demonstrated moderate to low levels of the protein. p53 over-expression was statistically significantly correlated to the mitotic index of the examined cases (p-value=0.001). Interestingly, the atypical/anaplastic group of histotypes demonstrated the strongest p53 expression rates compared to the others (p-value=0.001). CONCLUSION: p53 overexpression is observed in a broad spectrum of meningiomas. High expression levels lead to an aggressive biological behavior of the malignancy (combined with increased mitotic rates), especially in atypical and anaplastic sub-types that also have a high recurrence rate.
BACKGROUND/AIM: Meningiomas represent the main intracranial primary central nervous system (CNS) tumour in adults worldwide. Oncogenes' over-activation combined with suppressor genes' silencing affect negatively the biological behavior of these neoplasms. This study aimed to explore the impact of p53 suppressor gene expression in meningiomas' clinic-pathological features based on a combination of sophisticated techniques. MATERIALS AND METHODS: Fifty (n=50) meningiomas were included in the study, comprising a broad spectrum of histopathological subtypes. An immunohistochemistry assay was applied on tissue microarray cores followed by digital image analysis. RESULTS: p53 protein over-expression (high staining intensity levels) was observed in 27/50 (54%) cases, whereas the rest (23/50-/46%) demonstrated moderate to low levels of the protein. p53 over-expression was statistically significantly correlated to the mitotic index of the examined cases (p-value=0.001). Interestingly, the atypical/anaplastic group of histotypes demonstrated the strongest p53 expression rates compared to the others (p-value=0.001). CONCLUSION: p53 overexpression is observed in a broad spectrum of meningiomas. High expression levels lead to an aggressive biological behavior of the malignancy (combined with increased mitotic rates), especially in atypical and anaplastic sub-types that also have a high recurrence rate.
Authors: Ege Ülgen; Pınar Kuru Bektaşoğlu; M Aydın Sav; Özge Can; Ayça Erşen Danyeli; Deniz Baycın Hızal; M Necmettin Pamir; Koray Özduman Journal: World Neurosurg Date: 2018-11-29 Impact factor: 2.104